Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Pfizer collaboration revenue		$ 29,509	$ 0
Total revenues		41,063	33,333
Research and development		30,880	44,186
Selling, general and administrative	[1]	61,212	22,828
Total operating costs and expenses		98,385	67,014
Loss from operations		(57,322)	(33,681)
Interest expense	[2]	3,505	2,184
Interest income		(78)	(108)
Foreign exchange gain		0	(3,569)
Loss before income taxes		(60,749)	(32,188)
Income tax expense		911	672
Net loss		$ (61,660)	$ (32,860)
Net loss per common share - basic (in USD per share)		$ (0.67)	$ (0.37)
Net loss per common share - diluted (in USD per share)		$ (0.67)	$ (0.37)
Weighted average common shares outstanding - basic (in shares)		91,637,151	89,300,210
Weighted average common shares outstanding - diluted (in shares)		91,637,151	89,300,210
Product revenue, net
Revenues		$ 11,554	$ 0
Cost of revenue		1,032	0
Richter license and milestone revenue
Revenues		0	33,333
Collaboration expense to Pfizer
Cost of revenue		5,261	0
Majority Shareholder
Selling, general and administrative		1,323	114
Sumitomo Dainippon Pharma Co., Ltd. | Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd.
Interest expense		$ 2,904	$ 2,184

[1] Includes $1,323 and $114 of related party expense (inclusive of third-party pass-through costs) for the three months ended June 30, 2021 and 2020, respectively (see Note 5).

[2] Includes $2,904 and $2,184 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three months ended June 30, 2021 and 2020, respectively (see Note 5).